Seqirus gets FDA nod for AudenzThe FDA has approved the first adjuvanted, cell-based Pandemic Influenza A (H5N1) vaccine. FDA approves Teva's Ajovy auto-injector deviceAjovy offers patients the flexibility of quarterly 675 mg or monthly 225 mg dosing options. Boehringer Ingelheim, Lilly get FDA green light for Trijardy The FDA has approved Trijardy, the only triple-combination tablet with Jardiance for adults with Type 2 diabetes. Epizyme gets FDA nod for Tazverik Tazverik offers the first treatment option for patients with a rare soft tissue cancer. FDA approves new formulation, indication for Merck’s Dificid Merck has received the FDA's blessing for a pediatric indication for Dificid, as well as an oral suspension formulation. Merck to acquire ArQule Merck’s acquisition of ArQule diversifies its oncology pipeline. Ironwood, Allergan settle patent suit with Teva The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg Linzess is March 2029. FDA clears Horizon Therapeutics’ Tepezza Tepezza is the first approved treatment for thyroid eye disease. Hikma, Arecor to develop ready-to-use injectable medicine Hikma and Arecor's new product uses Arecor’s drug formulation technology platform Arestat. Lilly to offer two more lower-priced versions of insulin products The list price for Lill's Humalog Mix75/25 KwikPen and Humalog Junior KwikPen will be 50% less than branded versions. First Previous 30 31 32 33 34 Next Last
